MarketCap
Facebook
X
Telegram
Aeglea BioTherapeutics Net Income | AGLE
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Aeglea BioTherapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -155 M | -208 M | -339 M | -83.8 M | -65.8 M | -80.9 M | -78.3 M | -44.3 M | -27.2 M | -21.7 M | -11.3 M | -10.3 M | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -10.3 M | -339 M | -93.8 M |
Quarterly Net Income Aeglea BioTherapeutics
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -36.2 M | -69 M | - | -11.2 M | -36.7 M | -44.8 M | - | -69 M | -38.8 M | -43.9 M | - | -40.1 M | -217 M | -18.4 M | - | -18.2 M | -22.3 M | -24.4 M | - | -20.3 M | -6.83 M | -18.2 M | -22.7 M | -18 M | -21.4 M | -18.7 M | -21.5 M | -21.6 M | -18 M | -17.2 M | -14.9 M | -11.9 M | -9.41 M | -8.12 M | -6.48 M | -7.87 M | -6.63 M | -6.25 M | -5.48 M | -6.24 M | -5.43 M | -4.55 M | -3.99 M | -3.41 M | -1.43 M | -2.47 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -1.43 M | -217 M | -24.4 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Biotechnology industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Applied Genetic Technologies Corporation
AGTC
|
-18.4 M | - | - | $ 26.5 M |  USA |
 |
Achieve Life Sciences
ACHV
|
-54.6 M | $ 6.49 | -0.15 % | $ 283 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-32.2 M | - | - | $ 2.17 B | USA |
 |
Geron Corporation
GERN
|
-83.5 M | $ 1.12 | -0.88 % | $ 747 M | USA |
 |
Concert Pharmaceuticals
CNCE
|
-80.1 M | - | - | $ 401 M | USA |
 |
Aldeyra Therapeutics
ALDX
|
-33.8 M | $ 0.65 | 0.68 % | $ 39 M | USA |
 |
Gilead Sciences
GILD
|
8.51 B | $ 156.04 | -0.73 % | $ 194 B | USA |
 |
Genmab A/S
GMAB
|
7.84 B | $ 43.79 | 9.48 % | $ 2.83 B |  Danmark |
 |
Crinetics Pharmaceuticals
CRNX
|
-465 M | $ 84.95 | 0.13 % | $ 7.99 B | USA |
 |
ImmunoGen
IMGN
|
-223 M | - | - | $ 7.92 B | USA |
 |
Galectin Therapeutics
GALT
|
-30.8 M | $ 3.19 | -5.62 % | $ 204 M | USA |
 |
Genprex
GNPX
|
-16.2 M | $ 1.81 | -8.59 % | $ 1.69 M | USA |
 |
GeoVax Labs
GOVX
|
-21.5 M | $ 0.21 | -3.15 % | $ 201 K | USA |
 |
GlaxoSmithKline plc
GSK
|
6.29 B | $ 50.75 | -0.9 % | $ 206 B |  Britain |
 |
GT Biopharma
GTBP
|
-28.4 M | $ 5.46 | -1.09 % | $ 30.1 M | USA |
 |
Vascular Biogenics Ltd.
VBLT
|
-11.3 M | - | -8.77 % | $ 12.4 M |  Israel |
 |
Amarin Corporation plc
AMRN
|
-38.8 M | $ 11.79 | 1.64 % | $ 4.89 B |  Irlanda |
 |
Berkeley Lights
BLI
|
-98 M | - | -7.31 % | $ 87 M | USA |
 |
Histogen
HSTO
|
-10.6 M | - | 31.6 % | $ 2.12 M | USA |
 |
Halozyme Therapeutics
HALO
|
317 M | $ 125.63 | 0.88 % | $ 15.1 B | USA |
 |
Cidara Therapeutics
CDTX
|
-170 M | - | - | $ 1.41 B | USA |
 |
Hutchison China MediTech Limited
HCM
|
457 M | $ 14.36 | 0.56 % | $ 12.3 B |  China |
 |
AnaptysBio
ANAB
|
131 M | $ 48.73 | 1.31 % | $ 1.41 B | USA |
 |
Clovis Oncology
CLVS
|
-64.4 M | - | -7.23 % | $ 13 M | USA |
 |
Harmony Biosciences Holdings
HRMY
|
159 M | $ 36.13 | 0.28 % | $ 2.08 B | USA |
 |
Anika Therapeutics
ANIK
|
-10.9 M | $ 21.42 | 1.56 % | $ 307 M | USA |
 |
iBio
IBIO
|
-33 M | $ 0.72 | -8.44 % | $ 74.9 M | USA |
 |
Axon Enterprise
AXON
|
125 M | $ 420.37 | 1.39 % | $ 32.8 B | USA |
 |
Immunome
IMNM
|
-212 M | $ 17.99 | -1.48 % | $ 1.57 B | USA |
 |
Immuron Limited
IMRN
|
-5.22 M | $ 0.95 | 0.44 % | $ 219 M |  Australia |
 |
InMed Pharmaceuticals
INM
|
-12.6 M | $ 1.44 | 8.27 % | $ 6 M |  Canada |
 |
Inovio Pharmaceuticals
INO
|
-85 M | $ 0.9 | 6.94 % | $ 42.2 M | USA |
 |
Insmed Incorporated
INSM
|
-1.28 B | $ 93.39 | -1.76 % | $ 18.6 B | USA |
 |
Akari Therapeutics, Plc
AKTX
|
-17.3 M | $ 8.23 | 1.54 % | $ 554 B | Britain |
 |
Innoviva
INVA
|
271 M | $ 20.66 | -1.9 % | $ 1.39 B | USA |
 |
Ionis Pharmaceuticals
IONS
|
-381 M | $ 42.93 | -2.23 % | $ 6.87 B | USA |
 |
Kaleido Biosciences
KLDO
|
-90.3 M | - | -3.69 % | $ 12.4 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
314 M | $ 224.03 | -1.43 % | $ 29.3 B | USA |
 |
Aquestive Therapeutics
AQST
|
-83.8 M | $ 4.0 | -3.15 % | $ 428 M | USA |
 |
Ironwood Pharmaceuticals
IRWD
|
24 M | $ 3.46 | -3.08 % | $ 560 M | USA |
 |
Cyclerion Therapeutics
CYCN
|
-3.18 M | $ 34.99 | 3.77 % | $ 147 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
-65.8 M | $ 9.84 | -8.29 % | $ 269 M | Israel |
 |
Alector
ALEC
|
-143 M | $ 1.83 | -0.27 % | $ 188 M | USA |
 |
Inventiva S.A.
IVA
|
-184 M | $ 3.71 | 3.06 % | $ 222 M |  France |
 |
Johnson & Johnson
JNJ
|
26.8 B | $ 263.81 | -1.46 % | $ 635 B | USA |
 |
argenx SE
ARGX
|
1.29 B | $ 873.71 | -0.23 % | $ 53.6 B |  Niderland |
 |
Arcutis Biotherapeutics
ARQT
|
-16.1 M | $ 31.2 | -3.11 % | $ 3.97 B | USA |
 |
ObsEva SA
OBSV
|
-58.4 M | - | -15.52 % | $ 10.5 M |  Schweiz |
 |
Cocrystal Pharma
COCP
|
-8.83 M | $ 0.95 | 4.17 % | $ 10.7 M | USA |
 |
Ascendis Pharma A/S
ASND
|
-228 M | $ 243.37 | 0.16 % | $ 14.7 B | Danmark |